Search

Your search keyword '"Romana Jugooa"' showing total 3 results
Start Over Author "Romana Jugooa"
3 results on '"Romana Jugooa"'

1. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Author

Stefania Oliva, Davine Hofste op Bruinink, Lucie Rihova, Mattia D’Agostino, Lucia Pantani, Andrea Capra, Bronno van der Holt, Rossella Troia, Maria Teresa Petrucci, Tania Villanova, Pavla Vsianska, Romana Jugooa, Claudia Brandt-Hagens, Milena Gilestro, Massimo Offidani, Rossella Ribolla, Monica Galli, Roman Hajek, Francesca Gay, Michele Cavo, Paola Omedé, Vincent H. J. van der Velden, Mario Boccadoro, and Pieter Sonneveld

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed by bortezomib-lenalidomide-dexamethasone (VRd) versus no consolidation, and lenalidomide maintenance. Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based MFC protocols (eight colors, two tubes) with 10−4−10−5 sensitivity. At enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0.39; p

Published
2021
Full Text
View/download PDF

2. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies

Author

Martijn W. C. Verbeek, Chiara Buracchi, Anna Laqua, Stefan Nierkens, Lukasz Sedek, Juan Flores‐Montero, Mattias Hofmans, Elaine Sobral de Costa, Michaela Nováková, Ester Mejstrikova, Susana Barrena, Saskia Kohlscheen, Monika Szczepanowski, Jan Kulis, Elen Oliveira, Romana Jugooa, Anja X. Jong, Tomasz Szczepanski, Jan Philippé, Jacques J. M. Dongen, Alberto Orfao, Monika Brüggemann, Giuseppe Gaipa, Vincent H. J. Velden, Immunology, European Commission, European Hematology Association, Silesian University of Technology, Verbeek, M, Buracchi, C, Laqua, A, Nierkens, S, Sedek, L, Flores-Montero, J, Hofmans, M, Sobral de Costa, E, Novakova, M, Mejstrikova, E, Barrena, S, Kohlscheen, S, Szczepanowski, M, Kulis, J, Oliveira, E, Jugooa, R, de Jong, A, Szczepanski, T, Philippe, J, van Dongen, J, Orfao, A, Bruggemann, M, Gaipa, G, and van der Velden, V

Subjects
acute leukaemia, Neoplasm, Residual, Minimal residual disease, flow cytometry, Antigens, CD19, hemic and immune systems, Hematology, diagnostic haematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma, Acute leukaemia, body regions, Diagnostic haematology, hemic and lymphatic diseases, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Medicine and Health Sciences, minimal residual disease, Humans, Flow cytometry, Adaptor Proteins, Signal Transducing
Abstract

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct., The EuroFlow Consortium received support from the FP6-2004-LIFESCIHEALTH-5 programme of the European Commission (grant LSHB-CT-2006-018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato-Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA). TS and LS were supported by a Scientific Grant from the Medical University of Silesia Nr. PCN-1-050/K/0/K.

Published
2021

3. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Author

Claudia Brandt-Hagens, Stefania Oliva, Pavla Všianská, Maria Teresa Petrucci, Roman Hájek, Romana Jugooa, Monica Galli, Mattia D'Agostino, Rossella Ribolla, Davine Hofste op Bruinink, Pieter Sonneveld, Andrea Capra, Bronno van der Holt, Tania Villanova, Massimo Offidani, Michele Cavo, Lucia Pantani, Rossella Troia, Mario Boccadoro, Paola Omedè, Lucie Rihova, Milena Gilestro, Vincent H.J. van der Velden, Oliva S., Bruinink D.H., Rihova L., D'Agostino M., Pantani L., Capra A., van der Holt B., Troia R., Petrucci M.T., Villanova T., Vsianska P., Jugooa R., Brandt-Hagens C., Gilestro M., Offidani M., Ribolla R., Galli M., Hajek R., Gay F., Cavo M., Omede P., van der Velden V.H.J., Boccadoro M., Sonneveld P., Hematology, and Immunology

Subjects
Melphalan, Male, medicine.medical_specialty, Neoplasm, Residual, Population, Urology, Bone Marrow Cells, Article, Dexamethasone, Disease-Free Survival, Bortezomib, EuroFlow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Autograft, Humans, Medicine, Autografts, education, Lenalidomide, Multiple myeloma, RC254-282, education.field_of_study, Antineoplastic Combined Chemotherapy Protocol, medicine.diagnostic_test, business.industry, Hematopoietic Stem Cell Transplantation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Hematology, Translational research, Middle Aged, medicine.disease, Flow Cytometry, Minimal residual disease, body regions, Survival Rate, medicine.anatomical_structure, Risk factors, Oncology, Bone Marrow Cell, Female, Bone marrow, business, Multiple Myeloma, medicine.drug, Fluorescence in situ hybridization, Human
Abstract

Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed by bortezomib-lenalidomide-dexamethasone (VRd) versus no consolidation, and lenalidomide maintenance. Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based MFC protocols (eight colors, two tubes) with 10−4−10−5 sensitivity. At enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0.39; p p

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results